CRISPR Therapeutics reports remissions, one death in cancer cell therapy study
Bio Pharma Dive
OCTOBER 21, 2020
The biotech is one of several attempting to develop "off-the-shelf "CAR-T therapies. While trial results show potential, high-dose treatment was paused following a patient's death.
Let's personalize your content